{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:10:29Z","timestamp":1788934229945,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Comparing studies of molecular ancillary diagnostic tests for difficult-to-diagnose cutaneous melanocytic neoplasms presents a methodological challenge, given the disparate ways accuracy metrics are calculated. A recent report by Boothby-Shoemaker et al investigating the real-world accuracy of the 23-gene expression profile (23-GEP) test highlights this methodological difficulty, reporting lower accuracy than previously observed. However, their calculation method\u2014with indeterminate test results defined as either false positive or false negative\u2014was different than those used in previous studies. We corrected for these differences and recalculated their reported accuracy metrics in the same manner as the previous studies to enable appropriate comparison with previously published reports. This corrected analysis showed a sensitivity of 92.1% (95% confidence interval [CI], 82.1%\u2013100%) and specificity of 94.4% (91.6%\u201396.9%). We then compared these results directly to previous studies with &gt;25 benign and &gt;25 malignant cases with outcomes and\/or concordant histopathological diagnosis by \u22653 dermatopathologists. All studies assessed had enrollment imbalances of benign versus malignant patients (0.8\u20137.0 ratio), so balanced cohorts were resampled according to the lowest common denominator to calculate point estimates and CIs for accuracy metrics. Overall, we found no statistically significant differences in the ranges of 23-GEP sensitivity, 90.4%\u201396.3% (95% CI, 80.8%\u2013100%), specificity, 87.3%\u201396.2% (78.2%\u2013100%), positive predictive value, 88.5%\u201396.1% (81.5%\u2013100%), or negative predictive value, 91.1%\u201396.3% (83.6%\u2013100%) between previous studies and the cohort from Boothby-Shoemaker et al with this unified methodological approach. Rigorous standardization of calculation methods is necessary when the goal is direct cross-study comparability.<\/jats:p>","DOI":"10.1097\/dad.0000000000002808","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T19:00:10Z","timestamp":1723662010000},"page":"833-838","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Appropriate Statistical Methods to Assess Cross-study Diagnostic 23-Gene Expression Profile Test Performance for Cutaneous Melanocytic Neoplasms"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5186-6491","authenticated-orcid":false,"given":"Matthew S.","family":"Goldberg","sequence":"first","affiliation":[{"name":"Castle Biosciences, Inc., Friendswood, TX;"},{"name":"Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay J.","family":"Cockerell","sequence":"additional","affiliation":[{"name":"Cockerell Dermatopathology, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Castle Biosciences, Inc., Friendswood, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Castle Biosciences, Inc., Friendswood, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke H.","family":"Russell","sequence":"additional","affiliation":[{"name":"Castle Biosciences, Inc., Friendswood, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Hosler","sequence":"additional","affiliation":[{"name":"ProPath\/Sonic Healthcare USA, Dallas, TX;"},{"name":"University of Texas Southwestern, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etan","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Kansas City University-Graduate Medical Education Consortium, Oviedo, FL; and"},{"name":"Advanced Dermatology and Cosmetic Surgery, Oviedo, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000002440","article-title":"Immunohistochemistry for PRAME in dermatopathology","volume":"45","author":"Lezcano","year":"2023","journal-title":"Am J Dermatopathol"},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.semdp.2021.12.003","article-title":"Immunohistochemistry in melanocytic lesions: updates with a practical review for pathologists","volume":"39","author":"Saleem","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/DAD.0000000000002501","article-title":"A comparison of preferentially expressed antigen in melanoma immunohistochemistry and diagnostic gene expression-profiling assay in challenging melanocytic proliferations","volume":"46","author":"Casillas","year":"2024","journal-title":"Am J Dermatopathol."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5858\/arpa.2014-0018-CP","article-title":"Best practices in diagnostic immunohistochemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma","volume":"139","author":"Dewar","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/DAD.0000000000002584","article-title":"Pitfalls of PRAME immunohistochemistry in a large series of melanocytic and nonmelanocytic lesions with literature review","volume":"46","author":"Turner","year":"2023","journal-title":"Am J Dermatopathol"},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ced\/llae005","article-title":"Comparison of S100A8 and PRAME as biomarkers for distinguishing melanoma from melanocytic nevus: a case-control analysis","volume":"49","author":"Hai","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/PAS.0b013e3181a1ef36","article-title":"Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"33","author":"Gerami","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/cup.13327","article-title":"Evidence behind the use of molecular tests in melanocytic lesions and practice patterns of these tests by dermatopathologists","volume":"45","author":"Emanuel","year":"2018","journal-title":"J Cutan Pathol"},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/DAD.0000000000000380","article-title":"Fluorescence in situ hybridization for melanoma diagnosis: a review and a reappraisal","volume":"38","author":"Ferrara","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.30385","article-title":"An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi","volume":"123","author":"Clarke","year":"2017","journal-title":"Cancer"},{"key":"R12-20250616","first-page":"12","article-title":"A physician\u2019s guide to the use of gene expression profile ancillary diagnostic testing for cutaneous melanocytic neoplasms","volume":"16","author":"Marks","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2023.05.002","article-title":"Ancillary testing for melanoma: current trends and practical considerations","volume":"140","author":"Hosler","year":"2023","journal-title":"Hum Pathol."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cup.14135","article-title":"Appropriate use criteria for ancillary diagnostic testing in dermatopathology: new recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee","volume":"49","author":"Fung","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0272989X8700700208","article-title":"Intermediate, indeterminate, and uninterpretable diagnostic test results","volume":"7","author":"Simel","year":"1987","journal-title":"Med Decis Making"},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"642380","DOI":"10.3389\/fmed.2021.642380","article-title":"Molecular biomarkers for melanoma screening, diagnosis and prognosis: current state and future prospects","volume":"8","author":"Deacon","year":"2021","journal-title":"Front Med."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/DAD.0000000000001713","article-title":"Concordance analysis of the 23-gene expression signature (myPath melanoma) with fluorescence in situ hybridization assay and single nucleotide polymorphism array in the analysis of challenging melanocytic lesions: results from an academic medical center","volume":"42","author":"Castillo","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.humpath.2023.07.002","article-title":"Real world validation of an adjunctive gene expression profiling assay for melanoma diagnosis and correlation with clinical outcomes at an academic center","volume":"139","author":"Boothby-Shoemaker","year":"2023","journal-title":"Hum Pathol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-16-0958","article-title":"Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes","volume":"26","author":"Ko","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.humpath.2018.12.001","article-title":"Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions","volume":"86","author":"Ko","year":"2019","journal-title":"Hum Pathol"},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pme-2020-0048","article-title":"Clinical validity of a gene expression signature in diagnostically uncertain neoplasms","volume":"17","author":"Clarke","year":"2020","journal-title":"Personalized Med"},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41379-018-0087-6","article-title":"Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms","volume":"31","author":"Reimann","year":"2018","journal-title":"Mod Pathol."},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/modpathol.2016.84","article-title":"Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions","volume":"29","author":"Minca","year":"2016","journal-title":"Mod Pathol."},{"key":"R27-20250616","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3390\/diagnostics12092197","article-title":"PRAME immunoexpression in 275 cutaneous melanocytic lesions: a double institutional experience","volume":"12","author":"Cazzato","year":"2022","journal-title":"Diagnostics"},{"key":"R28-20250616","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/cancers13153864","article-title":"Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas","volume":"13","author":"Gassenmaier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R29-20250616","doi-asserted-by":"crossref","first-page":"e0223832","DOI":"10.1371\/journal.pone.0223832","article-title":"Diagnostic test evaluation methodology: a systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard\u2014an update","volume":"14","author":"Umemneku Chikere","year":"2019","journal-title":"PLoS One"},{"key":"R30-20250616","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41379-018-0197-1","article-title":"Reply to Reimann et al","volume":"32","author":"Clarke","year":"2019","journal-title":"Mod Pathol."},{"key":"R31-20250616","doi-asserted-by":"crossref","first-page":"264","DOI":"10.12788\/cutis.0254","article-title":"Clinical use of a diagnostic gene expression signature for melanocytic neoplasms","volume":"107","author":"Tschen","year":"2021","journal-title":"Cutis"},{"key":"R32-20250616","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/bmm.15.11","article-title":"Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions","volume":"9","author":"Warf","year":"2015","journal-title":"Biomarkers Med"},{"key":"R33-20250616","doi-asserted-by":"crossref","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:03:14Z","timestamp":1750096994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002808","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}